Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism

NCT00975000 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00975000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00975000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 3, 2009
Completion date
April 16, 2013
Enrollment
114 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

chronic allograft nephropathy, chronic kidney disease, chronic renal failure, disordered mineral metabolism, end stage renal disease, hyperparathyroidism, hypophosphatemia, kidney disease, kidney transplantation, post renal transplantation